Isomorphic Labs, Spinout from Google DeepMind, Considering Funding Round with Valuation Between $40B and $50B
Isomorphic Labs, an AI-driven drug discovery startup spun out of Alphabet Inc.'s Google DeepMind, is in early discussions to raise new capital at a valuation estimated between $40 billion and $50 billion. According to Bloomberg, the funding round could significantly increase Isomorphic's current value as it seeks further investment for its research initiatives. The company leverages artificial intelligence to accelerate drug discovery processes, aiming to revolutionize pharmaceutical development by reducing time-to-market for new treatments. This potential fundraising effort highlights growing investor interest in AI applications within healthcare and biotechnology sectors. Such a high valuation underscores the market's confidence in Isomorphic’s technology and its ability to disrupt traditional methods of drug research and development.
Tickers: $GOOG